MedTrace Logo

Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease

NCT04531189 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2022-04-29

No results posted yet for this study

Summary

The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future clinical studies.

Conditions

  • Wilson Disease

Sponsors & Collaborators

Principal Investigators

  • Ultragenyx Medical Director · Ultragenyx Pharmaceutical

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2022-03-25
Completion
2022-03-25

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531189 on ClinicalTrials.gov